{"commentary":{"count":6,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":3,"podcast":2,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"TORCHLIGHT","nct_id":"NCT04085276","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=torchlight-nct04085276. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"TORCHLIGHT","arms":[{"description":"Patients will receive both JS001 and Nab-Paclitaxel.","label":"JS001 Plus Nab-Paclitaxel","type":"EXPERIMENTAL"},{"description":"Patients will receive both placebo and Nab-Paclitaxel.","label":"Placebo Plus Nab-Paclitaxel","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-02-28","type":"ACTUAL"},"conditions":["Triple-Negative Breast Cancer"],"enrollment":{"count":531,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"JS001","type":"DRUG"},{"name":"Nab-Paclitaxel","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Nab-Paclitaxel","type":"DRUG"}],"last_update":"2026-04-16","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","official_title":"A Randomized, Double-Blind, Multicenter, Phase III Study of Toripalimab(JS001) in Combination With Nab-Paclitaxel Versus Placebo Plus Nab-Paclitaxel for Patients With Metastatic or Recurrent Triple-Negative Breast Cancer With or Without Systemic Treatment (TORCHLIGHT)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intend to Treat patients.","timeFrame":"Up to approximately 61 months from first patient in."},{"measure":"PFS assessed by BICR using RECIST v1.1 in PD-L1 positive patients","timeFrame":"Up to approximately 61 months from first patient in."}],"references":[],"start_date":{"date":"2018-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment","url":"https://clinicaltrials.gov/study/NCT04085276"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/torchlight-nct04085276"}